ContractPatent Transfer Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
SERVICE AGREEMENTService Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances) • Delaware
This Agreement (the “Agreement”) is entered into on April 6, 2017 by and between Entera Bio Ltd., an Israel corporation, having its principal offices at Hadassah Medical Center, Kiryat Hadassah, PO Box 12117, Jerusalem, Israel (the “Company”), and Luke Beshar of 12 Lorraine Road, Summit, New Jersey 07901 (“Service Provider”).
ContractWarrant Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
THIS WARRANT AND THE APPLICABLE SHARES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SHARES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT.
ContractWarrant Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
THIS WARRANT AND THE APPLICABLE SHARES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SHARES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT.
CONVERTIBLE FINANCING AGREEMENTConvertible Financing Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
This Convertible Financing Agreement (the “Agreement”) is made and entered into as of the 31 day of December, 2012, by and among Entera Bio Ltd., a company incorporated under the laws of the State of Israel having its principal offices at 3 Avishai St, Jerusalem 93149, Israel (the “Company”); D.N.A. Biomedical Solutions Ltd. (“D.N.A.”) and the investors set out in Exhibit l hereto (the “Investors”, and each individually, an “Investor”).
SERIES A PREFERRED SHARE PURCHASE AGREEMENTSeries a Preferred Share Purchase Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
THIS SERIES A PREFERRED SHARE PURCHASE AGREEMENT (the “Agreement”) is made as of the 29th day of January 2014 (the “Effective Date”), by and between Entera Bio Ltd., an Israeli company (the “Company”) and Centillion Fund (the “Investor”).
ContractSeries a Preferred Share Purchase Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
AMENDMENT TO SERIES A PREFERRED SHARE PURCHASE AGREEMENTSeries a Preferred Share Purchase Agreement • November 9th, 2017 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
This Amendment (this “Amendment”), dated June 18, 2014, amends that certain Series A Preferred Share Purchase Agreement by and between EnteraBio Ltd. and Centillion Fund, dated January 29, 2014 (the “SPA”) as follows:
